Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) EBITDA (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed EBITDA for 6 consecutive years, with -$3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 680.24% to -$3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.0 million, a 74.91% decrease, with the full-year FY2024 number at -$6.7 million, up 37.21% from a year prior.
  • EBITDA was -$3.7 million for Q3 2025 at Ensysce Biosciences, down from -$1.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $644746.0 in Q3 2024 to a low of -$16.9 million in Q3 2021.
  • A 5-year average of -$3.6 million and a median of -$2.6 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 4071.91% in 2021, then skyrocketed 123.81% in 2024.
  • Ensysce Biosciences' EBITDA stood at -$2.0 million in 2021, then tumbled by 209.0% to -$6.2 million in 2022, then skyrocketed by 49.11% to -$3.2 million in 2023, then fell by 13.33% to -$3.6 million in 2024, then decreased by 4.6% to -$3.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's EBITDA are -$3.7 million (Q3 2025), -$1.8 million (Q2 2025), and -$2.0 million (Q1 2025).